We are committed to serving the best interests of our shareholders.

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary TESARO to Announce Third-Quarter 2017 Financial Results on November 7, 2017
WALTHAM, Mass. , Oct. 24, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its third-quarter 2017 financial results on Tuesday, November 7, 2017 , after the close of the U.S. financial markets. TESARO’s senior management team will host a conference call and live audio webcast at
View HTML
Toggle Summary TESARO Announces Participation at Two Investor Conferences
WALTHAM, Mass. , Oct. 23, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are: The Credit Suisse 26 th Annual Healthcare Conference at The Phoenician in
View HTML
Toggle Summary The Foundation for Women’s Cancer and TESARO Announce 2nd Year of Partnership Supporting the National Race to End Women’s Cancer
CHICAGO and WALTHAM, Mass. , Oct. 18, 2017 (GLOBE NEWSWIRE) -- The Foundation for Women’s Cancer (FWC), the official foundation of the Society of Gynecologic Oncology , and TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the continuation of their
View HTML
Toggle Summary TESARO Expands Our Way Forward Program for the Ovarian Cancer Community and Partners With Olympic Gymnast Shannon Miller
 Gold-Medal Gymnast and Ovarian Cancer Survivor Shannon Miller Will Broaden Awareness About Advanced Ovarian Cancer as a Continuation of the Our Way Forward Program WALTHAM, Mass. , Sept. 28, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company,
View HTML
Toggle Summary TESARO Receives Positive CHMP Opinion for ZEJULA®
ZUG, Switzerland , Sept. 15, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the Company’s marketing
View HTML
Toggle Summary TESARO Summarizes ZEJULA and TSR-042 Data Presented at the 2017 ESMO Annual Meeting
MADRID, Spain, Sept. 11, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today provided a summary of ZEJULA and TSR-042, an anti-PD-1 antibody, data presented at the 2017 European Society of Medical Oncology (ESMO) Annual Meeting in Madrid.
View HTML
Toggle Summary TESARO Announces Nine Data Presentations at the 2017 European Society for Medical Oncology (ESMO) Annual Meeting
WALTHAM, Mass., Aug. 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that data from nine abstracts will be presented at the 2017 European Society for Medical Oncology (ESMO) annual meeting, September 8 to September 12, 2017, in
View HTML
Toggle Summary TESARO Announces Participation at Four Investor Conferences
WALTHAM, Mass., Aug. 23, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in four upcoming investor conferences. The four conferences are: The Wells Fargo Global Healthcare Conference at the Westin
View HTML
Toggle Summary TESARO Announces Second-Quarter 2017 Operating Results
ZEJULA is the most prescribed PARP inhibitor in U.S.; Q2 net sales totaled $26 million in first quarter of availability Recently opened European niraparib EAP has enrolled 200 patients VARUBY oral launch now underway in Europe Dose-escalation of TSR-022 (anti-TIM-3) completed and combination trial
View HTML
Toggle Summary TESARO and Takeda Enter Into Exclusive Licensing Agreement to Develop and Commercialize Novel Cancer Therapy Niraparib in Japan
— Takeda's Rights Include all Potential Indications for Niraparib in Japan and Rights Excluding Prostate Cancer in South Korea, Taiwan, Russia and Australia — TESARO to Receive $ 100 Million Upfront Payment and is Eligible for Future Regulatory and Commercial Milestones, Plus Royalties
View HTML